Terms: = Germ cell tumor AND TNFRSF14, Q92956, 8764, ENSG00000157873, TR2, ATAR, LIGHTR, HVEM, HVEA
22 results:
1. T cells Expressing CAR Equipped With Extracellular Domain of BTLA Are Effective Against hvem-over-expressing Melanoma cell Lines.
Kim Y; Kim JE; Lee DY; Choi JU; Park JS; Lee HK; Choi SU; Park S; Park CH
Anticancer Res; 2023 Aug; 43(8):3419-3427. PubMed ID: 37500142
[TBL] [Abstract] [Full Text] [Related]
2. SOX10 Inhibits T cell Recognition by Inducing Expression of the Immune Checkpoint Molecule PD-L1 in A375 Melanoma cells.
Sasaki K; Hirohashi Y; Murata K; Minowa T; Nakatsugawa M; Murai A; Mizue Y; Kubo T; Kanaseki T; Tsukahara T; Iwabuchi S; Hashimoto S; Uhara H; Ishida-Yamamoto A; Torigoe T
Anticancer Res; 2023 Apr; 43(4):1477-1484. PubMed ID: 36974807
[TBL] [Abstract] [Full Text] [Related]
3. Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Schatz J; Ladinig A; Fietkau R; Putz F; Gaipl US; Frey B; Derer A
Strahlenther Onkol; 2023 Dec; 199(12):1140-1151. PubMed ID: 36480032
[TBL] [Abstract] [Full Text] [Related]
4. Detailed
Stoll E; Hader M; Rückert M; Weissmann T; Lettmaier S; Putz F; Hecht M; Fietkau R; Rosin A; Frey B; Gaipl US
Int J Hyperthermia; 2022; 39(1):796-805. PubMed ID: 35676615
[TBL] [Abstract] [Full Text] [Related]
5. Cytokine and Chemokine Receptor Patterns of Human Malignant Melanoma cell Lines.
Koroknai V; Szász I; Jámbor K; Balázs M
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269787
[TBL] [Abstract] [Full Text] [Related]
6. Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.
Rossi E; Zizzari IG; Di Filippo A; Acampora A; Pagliara MM; Sammarco MG; Simmaco M; Lionetto L; Botticelli A; Bria E; Marchetti P; Blasi MA; Tortora G; Schinzari G; Nuti M
Hum Vaccin Immunother; 2022 May; 18(3):2034377. PubMed ID: 35258435
[TBL] [Abstract] [Full Text] [Related]
7. Interacting Genetic Lesions of Melanoma in the tumor Microenvironment: Defining a Viable Therapy.
Maniyar RR; Chakraborty S; Jarboe T; Suriano R; Wallack M; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():123-143. PubMed ID: 34888847
[TBL] [Abstract] [Full Text] [Related]
8. SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects.
Rosenbaum SR; Tiago M; Caksa S; Capparelli C; Purwin TJ; Kumar G; Glasheen M; Pomante D; Kotas D; Chervoneva I; Aplin AE
Cell Rep; 2021 Dec; 37(10):110085. PubMed ID: 34879275
[TBL] [Abstract] [Full Text] [Related]
9. The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?
Ballotti R; Cheli Y; Bertolotto C
Mol Cancer; 2020 Dec; 19(1):170. PubMed ID: 33276788
[TBL] [Abstract] [Full Text] [Related]
10. Melanoma-associated fibroblasts impair CD8+ T cell function and modify expression of immune checkpoint regulators via increased arginase activity.
Érsek B; Silló P; Cakir U; Molnár V; Bencsik A; Mayer B; Mezey E; Kárpáti S; Pós Z; Németh K
Cell Mol Life Sci; 2021 Jan; 78(2):661-673. PubMed ID: 32328671
[TBL] [Abstract] [Full Text] [Related]
11. Immune checkpoint molecule herpes virus entry mediator is overexpressed and associated with poor prognosis in human glioblastoma.
Han MZ; Wang S; Zhao WB; Ni SL; Yang N; Kong Y; Huang B; Chen AJ; Li XG; Wang J; Wang DH
EBioMedicine; 2019 May; 43():159-170. PubMed ID: 30987862
[TBL] [Abstract] [Full Text] [Related]
12. Differential modulation and prognostic values of immune-escape genes in uveal melanoma.
Basile MS; Mazzon E; Russo A; Mammana S; Longo A; Bonfiglio V; Fallico M; Caltabiano R; Fagone P; Nicoletti F; Avitabile T; Reibaldi M
PLoS One; 2019; 14(1):e0210276. PubMed ID: 30653520
[TBL] [Abstract] [Full Text] [Related]
13. Targetable T-type Calcium Channels Drive Glioblastoma.
Zhang Y; Cruickshanks N; Yuan F; Wang B; Pahuski M; Wulfkuhle J; Gallagher I; Koeppel AF; Hatef S; Papanicolas C; Lee J; Bar EE; Schiff D; Turner SD; Petricoin EF; Gray LS; Abounader R
Cancer Res; 2017 Jul; 77(13):3479-3490. PubMed ID: 28512247
[TBL] [Abstract] [Full Text] [Related]
14. Sentinel lymph node biopsy plus wide local excision vs. wide location excision alone for primary cutaneous melanoma: a systematic review and meta-analysis.
Santos-Juanes J; Fernández-Vega I; Galache Osuna C; Coto-Segura P; Martínez-Camblor P
J Eur Acad Dermatol Venereol; 2017 Feb; 31(2):241-246. PubMed ID: 27592851
[TBL] [Abstract] [Full Text] [Related]
15. CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells.
Thibult ML; Rivals JP; Mamessier E; Gertner-Dardenne J; Pastor S; Speiser DE; Derré L; Olive D
J Mol Med (Berl); 2013 Feb; 91(2):195-205. PubMed ID: 22903545
[TBL] [Abstract] [Full Text] [Related]
16. [Generation of a herpes simplex virus-permissive mouse melanoma cell line B16RHSV].
Zhuang XF; Zhou AP; Shi GL; Han XP; Li J; Zhang Y; Zhang YH; Zhang SR; Liu BL
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):187-91. PubMed ID: 22780971
[TBL] [Abstract] [Full Text] [Related]
17. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.
Derré L; Rivals JP; Jandus C; Pastor S; Rimoldi D; Romero P; Michielin O; Olive D; Speiser DE
J Clin Invest; 2010 Jan; 120(1):157-67. PubMed ID: 20038811
[TBL] [Abstract] [Full Text] [Related]
18. Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study.
Longoni M; Orzan F; Stroppi M; Boari N; Mortini P; Riva P
Neuro Oncol; 2008 Feb; 10(1):52-60. PubMed ID: 18094369
[TBL] [Abstract] [Full Text] [Related]
19. Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/tr2 also contributes to TRAIL resistance in NB.
Yang X; Merchant MS; Romero ME; Tsokos M; Wexler LH; Kontny U; Mackall CL; Thiele CJ
Cancer Res; 2003 Mar; 63(5):1122-9. PubMed ID: 12615731
[TBL] [Abstract] [Full Text] [Related]
20. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.
Iwasaki I; Sugiyama H; Kanazawa S; Hemmi H
Cancer Chemother Pharmacol; 2002 Jun; 49(6):438-44. PubMed ID: 12107547
[TBL] [Abstract] [Full Text] [Related]
[Next]
